These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 36916171)

  • 1. Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm.
    Hsu YC; Tseng CH; Kao JH
    Clin Mol Hepatol; 2023 Oct; 29(4):869-890. PubMed ID: 36916171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy.
    Hui RW; Mak LY; Seto WK; Yuen MF; Fung J
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):443-450. PubMed ID: 36972516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B.
    Wong GL; Chan HL; Yuen BW; Tse YK; Luk HW; Yip TC; Hui VW; Liang LY; Lee HW; Lui GC; Wong VW
    Liver Int; 2020 Mar; 40(3):549-557. PubMed ID: 31845462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Saitoh S; Arase Y; Kobayashi M; Kumada H
    J Gastroenterol; 2024 Jan; 59(1):34-44. PubMed ID: 37837569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B.
    Tout I; Lampertico P; Berg T; Asselah T
    Antiviral Res; 2021 Jan; 185():104992. PubMed ID: 33279523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice.
    Hsu YC; Wu JL; Tseng CH; Nguyen MH; Lin CW; Hung CL
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1413-1415.e3. PubMed ID: 34464721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
    Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
    Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
    Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
    Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When can we stop nucleoside analogues in patients with chronic hepatitis B?
    Chong CH; Lim SG
    Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
    Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
    Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B.
    Liem KS; Chi H; Fung S; Wong DK; Yim C; Noureldin S; Chen J; de Man RA; Sarowar A; Feld JJ; Hansen BE; Hou J; Peng J; Janssen HLA
    J Viral Hepat; 2022 Nov; 29(11):986-993. PubMed ID: 36048970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss.
    Zimmer CL; Rinker F; Höner Zu Siederdissen C; Manns MP; Wedemeyer H; Cornberg M; Björkström NK
    J Infect Dis; 2018 Apr; 217(10):1656-1666. PubMed ID: 29471497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Kim MA; Kim SU; Sinn DH; Jang JW; Lim YS; Ahn SH; Shim JJ; Seo YS; Baek YH; Kim SG; Kim YS; Kim JH; Choe WH; Yim HJ; Lee HW; Kwon JH; Lee SW; Jang JY; Kim HY; Park Y; Kim GA; Yang H; Lee HA; Koh M; Lee YS; Kim M; Chang Y; Kim YJ; Yoon JH; Zoulim F; Lee JH
    Gut; 2020 Dec; 69(12):2214-2222. PubMed ID: 32209606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Chang ML; Liaw YF; Hadziyannis SJ
    Aliment Pharmacol Ther; 2015 Aug; 42(3):243-57. PubMed ID: 26151841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference
    Cornberg M; Lok AS; Terrault NA; Zoulim F;
    J Hepatol; 2020 Mar; 72(3):539-557. PubMed ID: 31730789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.